Catalyst Biosciences

Equities

CBIO

US14888D2080

Real-time Estimate Cboe BZX Other stock markets 10:23:45 2024-04-16 am EDT			5-day change	1st Jan Change
15.87 ^USD	-3.70%		-2.25%	+106.66%

2023	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI
2023	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	CI

Catalyst Biosciences : Investor presentation 4.7 MB

November 15, 2021 at 01:15 pm EST

CATALYST BIOSCIENCES

Corporate Overview

15 November 2021

Forward looking statements

Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-looking statements. This press release contains forward-lookingstatements that involve substantial risks and uncertainties. Forward-lookingstatements include, without limitation, our plans to submit an IND for CB 4332 and begin clinical trials, announce a development candidate from our ProTUNE™ platform, continue to support Biogen in the development of CB 2782-PEG, and reduce the Company's burn rate by stopping development of MarzAA, as well as statements about the product candidates of Catalyst Biosciences, Inc. (the "Company") and the benefits of its protease engineering platform.

Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward- looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that the FDA may not agree to our clinical trial plan for CB 4332, that Biogen could terminate our agreement for the development of CB 2782-PEG, that the Company's complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that the Company may need to raise additional capital, and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

The Protease Medicines Company

Harnessing the catalytic power of proteases

Novel differentiated medicines

Robust complement portfolio

Unique expertise in protease engineering

Corporate strategy change announced 12 November

Path for long-term success

Stop MarzAA development	Focus on our protease medicines & complement
	therapeutics platform

MarzAA enrollment challenging
No longer feasible to deliver topline data in 2022
Plan to report data from MAA-304 obtained to date
Exploring opportunities to license or sell MarzAA & DalcA
Reduces burn rate significantly

Programs poised to achieve several value-creating milestones in 2022 and beyond
Move forward with CB 4332 clinical development

Complete transfer of CBIO supported activities to Biogen for CB 2782-PEG, our C3 degrader for the potential treatment of dry AMD
Generate candidates from our protease platform for licensing or internal development

Catalyst protease platform

Focus on complement therapeutics

CB 2782-PEG	CB 4332 Enhanced CFI
Best-in-class profile for dry AMD	Restoring balance to complement
Extended pharmacodynamics	in patients with dysregulated CFI

Novel C3-degrader	Engineered CFI entering
partnered to Bio for dry AMD	the clinic in 2022

Engineered proteases

Protease platforms tailored to restore function in specific indications

C4b C3b

ProTUNE™

PLATFORM

C3b/C4b degrader platform delivering candidates 2022

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

Catalyst Biosciences Inc. published this content on 15 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2021 18:14:06 UTC.

Latest news about Catalyst Biosciences

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	23-10-30	CI
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	23-10-29	CI
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	23-10-29	CI
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	23-10-26	CI
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	23-08-29	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	23-07-25	MT
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stocks Seen -2-	23-03-30	DJ
Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	23-03-01	MT
Wider-Than-Expected Trade in Goods Deficit Kicks Off Tuesday's Data Dump, Stifling US Equity Futures	23-02-28	MT
Top Premarket Gainers	23-02-28	MT
Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer	23-01-19	CI
Top Premarket Decliners	23-01-13	MT
GNI to Take Controlling Stake in Nasdaq-listed Catalyst Biosciences via Liver Fibrosis Drug Development Deals; Shares Up 3%	22-12-27	MT
Sector Update: Health Care Edging Higher at Tuesday Close	22-12-27	MT
Sector Update: Health Care Stocks Still Struggling for Direction	22-12-27	MT
Sector Update: Health Care	22-12-27	MT
Catalyst Biosciences Acquires F351, Controlling Interest in Continent From GNI Group	22-12-27	MT
Transcript : Catalyst Biosciences, Inc., GNI Group Ltd. - Special Call	22-12-27

Chart Catalyst Biosciences

Duration

Period

More charts

Company Profile

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Sector

More about the company

Income Statement Evolution

More financial data